Mesoblast Limited Interest Expense | MESO

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Mesoblast Limited

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
21.8 M	20.7 M	19.4 M	16.9 M	15.9 M	14.7 M	11.7 M	1.83 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
21.8 M	1.83 M	15.4 M

Quarterly Interest Expense Mesoblast Limited

2025-Q4	2025-Q2	2024-Q4	2024-Q2	2023-Q4	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
11.3 M	21.8 M	10.7 M	20.7 M	10.2 M	19.4 M	4.9 M	-	-	-	4.3 M	4.06 M	4.14 M	-	3.95 M	3.99 M	3.93 M	-	3.73 M	3.6 M	3.58 M	-	3.14 M	2.49 M	2.65 M	-	423 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
21.8 M	423 K	7.15 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
AbbVie ABBV	2.89 B	$ 263.04	0.49 %	$ 465 B	USA
AbCellera Biologics ABCL	-2.71 M	$ 11.41	2.15 %	$ 3.41 B	Canada
Aclaris Therapeutics ACRS	8.51 M	$ 5.53	6.02 %	$ 678 M	USA
ADC Therapeutics SA ADCT	22.7 M	$ 1.09	3.74 %	$ 139 M	Schweiz
Evelo Biosciences EVLO	61 K	-	-14.46 %	$ 27.9 M	USA
Allakos ALLK	-43 K	-	-	$ 28.6 M	USA
Clovis Oncology CLVS	53 K	-	-7.23 %	$ 13 M	USA
Chimerix CMRX	8.18 M	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	-309 K	-	-	$ 401 M	USA
ADMA Biologics ADMA	-212 K	$ 8.61	0.16 %	$ 2.05 B	USA
Eiger BioPharmaceuticals EIGR	5.47 M	-	-9.21 %	$ 2.55 M	USA
89bio ETNB	5.29 M	-	-	$ 1.55 B	USA
Freeline Therapeutics Holdings plc FRLN	2.15 M	-	-	$ 384 M	Britain
Fusion Pharmaceuticals FUSN	762 K	-	-	$ 1.41 B	Canada
Guardion Health Sciences GHSI	7.27 K	-	-0.31 %	$ 3.64 M	USA
Genocea Biosciences GNCA	1.12 M	-	-15.0 %	$ 3.04 M	USA
Gritstone Oncology GRTS	4.04 M	-	0.42 %	$ 213 M	USA
G1 Therapeutics GTHX	-5.32 M	-	-	$ 370 M	USA
Harpoon Therapeutics HARP	-11 K	-	-	$ 763 M	USA
Humanigen HGEN	2.92 M	-	-81.12 %	$ 4.28 M	USA
HOOKIPA Pharma HOOK	-3.25 M	-	-6.92 %	$ 79.4 M	USA
Intercept Pharmaceuticals ICPT	21.4 M	-	-	$ 643 M	USA
IGM Biosciences IGMS	-20 K	-	-	$ 76.9 M	USA
IMV IMV	2.34 K	-	-	$ 13.1 M	Canada
Intra-Cellular Therapies ITCI	36.8 K	-	-	$ 13.6 B	USA
Kinnate Biopharma KNTE	348 K	-	-	$ 123 M	USA
Chinook Therapeutics KDNY	-170 K	-	-	$ 2.6 B	USA
Kaleido Biosciences KLDO	2.84 M	-	-3.69 %	$ 12.4 M	USA
Kronos Bio KRON	3.89 M	-	1.49 %	$ 50.8 M	USA
Landos Biopharma LABP	1.2 M	-	0.58 %	$ 144 M	USA
La Jolla Pharmaceutical Company LJPC	733 K	-	-	$ 154 M	USA
LogicBio Therapeutics LOGC	1.07 M	-	-	$ 229 M	USA
Lumos Pharma LUMO	683 K	-	-	$ 35.3 M	USA
Merrimack Pharmaceuticals MACK	-191 K	-	-	$ 216 M	USA
Stealth BioTherapeutics Corp MITO	1.24 M	-	-	$ 23.9 M	USA
Mirati Therapeutics MRTX	19.2 M	-	-	$ 3.3 B	USA
NexImmune NEXI	-69.2 K	-	70.13 %	$ 4.12 M	USA
9 Meters Biopharma NMTR	2.67 M	-	-42.97 %	$ 1.05 M	USA
InVivo Therapeutics Holdings Corp. NVIV	1.3 M	-	-37.48 %	$ 476 K	USA
ObsEva SA OBSV	3.16 M	-	-15.52 %	$ 10.5 M	Schweiz
Oncorus ONCR	210 K	-	-8.54 %	$ 3.19 M	USA
OncoSec Medical Incorporated ONCS	20.9 K	-	31.87 %	$ 1.61 M	USA
Oncternal Therapeutics ONCT	33 K	-	-24.12 %	$ 1.56 M	USA
Opiant Pharmaceuticals OPNT	2.13 M	-	-	$ 109 M	USA
Orchard Therapeutics plc ORTX	3.08 M	-	1.02 %	$ 90.8 M	Britain